MARKET

ACRS

ACRS

Aclaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.520
+0.010
+0.22%
Closed 16:00 10/20 EDT
OPEN
4.650
PREV CLOSE
4.510
HIGH
4.700
LOW
4.320
VOLUME
463.01K
TURNOVER
--
52 WEEK HIGH
5.04
52 WEEK LOW
0.7000
MARKET CAP
193.11M
P/E (TTM)
-2.7033
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical Soft JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
WAYNE, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris’ Phase 2a clinical trial of ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, for the treatment of moderate to severe atopic dermatitis (AD). ATI-1777 was developed internally utilizing Aclaris’ proprietary KINect™ drug discovery platform. “We are excited about progressing this drug candidate into the clinic,” said Dr. David Gordon, Chief Medical Officer of Aclaris. “This trial is an important first step in the clinical development of ATI-1777 and we hope to establish that a topical JAK inhibitor can safely and effectively treat AD while limiting systemic exposure.”The Phase 2a trial is a multicenter, randomized, double-blind, vehicle-controlled, parallel-group trial to determine the efficacy, safety, tolerability and pharmacokinetics of ATI-1777 in subjects with moderate or severe AD. Subjects will apply ATI-1777 or vehicle twice daily for 28 days. Aclaris’ planned enrollment for this trial is approximately 42 subjects and the trial will be conducted in the U.S. The primary endpoint is the percentage change from baseline in the Eczema Area and Severity Index (EASI) score at week 4.About ATI-1777ATI-1777 is an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor. “Soft” JAK inhibitors are designed to provide JAK inhibition at the site of application and be rapidly metabolized in the systemic circulation. Aclaris plans to develop ATI-1777 as an emollient-containing spray formulation. Aclaris is developing ATI-1777 as a potential treatment for moderate to severe atopic dermatitis. About Aclaris Therapeutics, Inc.Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.Cautionary Note Regarding Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding ATI-1777 as a potential treatment for moderate to severe atopic dermatitis and the clinical development of ATI-1777. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the COVID-19 pandemic and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2019, Aclaris’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC filings” page of the Investors section of Aclaris’ website at https://www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.Aclaris Contactinvestors@aclaristx.com
GlobeNewswire · 20h ago
Dosing underway for Aclaris's ATI-1777 in mid-stage atopic dermatitis study
Aclaris Therapeutics (ACRS) has dosed the first patient in its Phase 2a trial evaluating ATI-1777 for the treatment of moderate to severe atopic dermatitis.ATI-1777 is an investigational topical “soft” Janus kinase 1/3
Seekingalpha · 21h ago
Aclaris Therapeutics Announces First Patient Dosed In Phase 2a Clinical Trial Of ATI-1777, An Investigational Topical Soft JAK 1/3 Inhibitor, For The Treatment Of Moderate To Severe Atopic Dermatitis
WAYNE, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today
Benzinga · 21h ago
Hedge Funds Are Buying Aclaris Therapeutics, Inc. (ACRS)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th, when the S&P 500 Index was trading around the […]
Insider Monkey · 6d ago
CORR, FATE, AKBA and DPW among after-hours movers
Gainers: [[AKBA]] +8%. [[FATE]] +5%. [[CHMA]] +3.5%. [[UAVS]] +3%. [[ZAGG]] +2%.Losers: [[KLIC]] -5.1%. [[ACRS]] -4.6%. [[LITB]] -2.9%. [[CORR]] -2.6%. [[DPW]] -1.3%.
Seekingalpha · 10/09 21:41
Precigen and Medigus lead Healthcare gainers; Mallinckrodt and GeoVax Labs lead losers
Gainers: Precigen (PGEN) +26%. Medigus (MDGS) +24%. Aclaris Therapeutics (ACRS) +17%. cbdMD (YCBD) +15%. Abeona Therapeutics (ABEO) +12%.Losers: Mallinckrodt (MNK) -18%. GeoVax Labs (GOVX) -13%. AgeX Therapeutics (AGE) -12%. COMPASS Pathways (CMPS) -9%. ThermoGenesis (THMO) -8%.
Seekingalpha · 10/09 15:01
The Daily Biotech Pulse: FDA Panel Review For Alkermes, Axovant Gets Rare Pediatric Disease Designation, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 8)
Benzinga · 10/09 11:20
The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7)
Benzinga · 10/08 11:52
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACRS. Analyze the recent business situations of Aclaris through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACRS stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 116
Institutional Holdings: 36.34M
% Owned: 85.05%
Shares Outstanding: 42.72M
TypeInstitutionsShares
Increased
13
1.31M
New
32
581.87K
Decreased
22
5.36M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
President/Chief Executive Officer/Co-Founder/Director
Neal Walker
Co-Founder/Chief Financial Officer
Frank Ruffo
Co-Founder/Chief Compliance Officer/Secretary
Kamil Ali-Jackson
Other
David Gordon
Director
Vincent Milano
Independent Director
Maxine Gowen
Independent Director
William Humphries
Independent Director
Anand Mehra
Independent Director
Christopher Molineaux
Independent Director
Andrew Powell
Independent Director
Bryan Reasons
Independent Director
Andrew Schiff
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACRS
Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. Its drug candidates are ATI-450, ATI-1777, ATI-2138, JAK1/JAK3 Inhibitor, A-101, ATI-501 and ATI-502. Its ATI-450, an investigational oral. small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. Its indirect, wholly owned subsidiary is Confluence Discovery Technologies, Inc.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aclaris Therapeutics Inc stock information, including NASDAQ:ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.